These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 6426554)
1. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products. Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554 [TBL] [Abstract][Full Text] [Related]
2. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors. Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536 [TBL] [Abstract][Full Text] [Related]
3. Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor. Chiabrando C; Broggini M; Castelli MG; Cozzi E; Castagnoli MN; Donelli MG; Garattini S; Giavazzi R; Fanelli R Cancer Res; 1987 Feb; 47(4):988-91. PubMed ID: 3100032 [TBL] [Abstract][Full Text] [Related]
4. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Bertele V; De Gaetano G Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787 [TBL] [Abstract][Full Text] [Related]
5. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Gresele P; Deckmyn H; Huybrechts E; Vermylen J Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299 [TBL] [Abstract][Full Text] [Related]
6. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor. Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343 [TBL] [Abstract][Full Text] [Related]
7. Thromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma. Orchard MA; Waddell KA; Lewis PJ; Blair IA Thromb Res; 1985 Sep; 39(6):701-10. PubMed ID: 3936223 [TBL] [Abstract][Full Text] [Related]
8. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Patscheke H; Stegmeier K Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261 [TBL] [Abstract][Full Text] [Related]
9. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour. Parry MJ Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997 [TBL] [Abstract][Full Text] [Related]
10. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. Gresele P; Blockmans D; Deckmyn H; Vermylen J J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542 [TBL] [Abstract][Full Text] [Related]
11. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
12. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro. O'Keefe EH; Liu EC; Greenberg R; Ogletree ML Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501 [TBL] [Abstract][Full Text] [Related]
13. Metabolism of arachidonic acid by macaque platelets. Implications for studies on atherosclerosis. Beatty CH; Howard CF; Hoskins MK; Herrington PT Atherosclerosis; 1985 Apr; 55(1):1-13. PubMed ID: 3924062 [TBL] [Abstract][Full Text] [Related]
14. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid. Patscheke H Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet aggregation and thromboxane production by pinacidil. Goodman RP; Little DM; Wright JT Prostaglandins Leukot Med; 1985 Aug; 19(2):115-22. PubMed ID: 3931098 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin synthesis by the cochlea. Kawata R; Urade Y; Tachibana M; Mizukoshi O Prostaglandins; 1988 Feb; 35(2):173-84. PubMed ID: 3129756 [TBL] [Abstract][Full Text] [Related]
17. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016 [TBL] [Abstract][Full Text] [Related]
18. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694 [TBL] [Abstract][Full Text] [Related]
19. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products]. Mevkh AT; Basevich VV; Varfolomeev SD Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]